GlassScriptPhysician profile
Kate E Zimmerly
NPI 1669831293
$3,762.42
in general payments reported to CMS, 2019-2025
24 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $647 · 2022: $800 · 2023: $1,288 · 2024: $758 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,315.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,018.15 | 2021-2025 | |
| Abbott Laboratories | $704.55 | 2021-2025 | Cardiomems, Mitraclip |
| Amgen INC. | $346.12 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $280.85 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $188.47 | 2022-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $186.31 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.83 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $135.15 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $121.17 | 2023 | |
| Abiomed | $119.60 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $89.15 | 2023 | Arcalyst |
| Pfizer INC. | $86.93 | 2021-2025 | |
| Csl Behring | $47.95 | 2023 | Kcentra |
| Actelion Pharmaceuticals US, INC. | $43.79 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $35.32 | 2023 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $25.86 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $25.84 | 2025 | |
| Biosense Webster, INC. | $24.30 | 2025 | |
| Medtronic, INC. | $21.66 | 2025 | Micra |
| Sanofi-Aventis U.S. LLC | $20.34 | 2024 | |
| Boston Scientific Corporation | $17.48 | 2022 | |
| Kestra Medical Technology Services, INC. | $17.41 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $16.45 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $13.74 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Zimmerly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.